Cloudman S91 – a responsive syngeneic melanoma model

Of all the skin cancer types, melanoma is the most serious form of skin cancer and while accounting for only about 1% of skin cancer cases, it is associated with the highest mortality1. Melanoma begins in melanocytes of the skin's epidermis, but once it becomes invasive into the skin or other parts of the body, it is more difficult to treat and can be fatal.

Combination therapies in oncology: The future of CAR T cell therapy for solid tumors?

Chimeric antigen receptor T cell (CAR T) therapy has demonstrated potentially curative therapeutic efficacies in patients with lymphoma and leukemia.1 This success in hematologic malignancies led to the application of CAR T cell therapy in solid tumors.

Measuring human cytokines in mouse samples in the discovery setting: Understanding immunoassay technology and managing the risk

Mouse models are commonly used in a variety of cancer-related investigations where they host human cells (1). While (immunocompromised) mouse models do have their pros and cons, the mouse remains a commonly utilized test system in preclinical oncology.

Analysis of the tumor-infiltrating myeloid subsets with high dimensional flow cytometry using the Expanded CompMyeloid™ panel

Labcorp Drug Development preclinical oncology offers the new mouse Expanded CompMyeloid™ panel, which provides deep immunophenotypic analysis into myeloid subsets known to regulate the tumor immune response.

Preclinical oncology imaging capabilities and expertise

Rapid non-invasive imaging technologies prove invaluable in diagnosing cancer and monitoring response to therapies. Many, such as magnetic resonance imaging (MRI) and X-ray computed tomography (CT), are an essential part of the clinical practice. In preclinical development, the widespread use of mouse models of disease for cancer requires the ability to image mouse models non-invasively to screen for potential drug targets, monitor disease development and therapeutic efficacy, and to detect biomarkers of drug efficacy quickly and in real time.1,2

Multiplex IHC for patterns of protein expression, co-expression, and spatial relationships

Multiplex immunohistochemistry (IHC) is an assay that utilizes the basic concept of single antigen staining to detect multiple markers at one time. It allows for the labeling capabilities of peroxidase, alkaline phosphatase and other conjugated primary or secondary antibodies and can be achieved using several common methods including indirect or direct staining protocols.

PC-3M-Luc-C6 – a model for prostate carcinoma

Early detection of prostate cancer is very challenging. Unfortunately patients are asymptomatic until advanced stage disease, leaving them with limited treatment options. The delayed detection also results in an increase in the incidence of metastatic disease. Advanced stage prostate cancer typically metastasizes to the bone and lymph nodes.

GL261-luc: A model for immunotherapy and radiation therapy

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer. GBM tumors grow within a fairly immunosuppressive tumor microenvironment and a relatively immune-privileged central nervous system. For patients diagnosed with GBM, prognosis remains poor with conventional therapies that include radiotherapy, chemotherapy, and surgery.

BT-474 Human ductal breast carcinoma: New life for an old model

The BT-474 cell line has a long history, but many of us thought it had run its natural course and was quickly becoming obsolete.

LL/2: an immunosuppressive murine tumor model

Lung cancer is the second most common cancer diagnosed in both men and women in the United States and is, by far, the most common cause of cancer-related deaths in men and women. In 2019, the American Cancer Society estimates that 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) will be diagnosed, and 142,670 deaths from lung cancer (76,650 in men and 66,020 in women) will occur.